The objective of this study was to directly compare the safety of tocilizumab (TCZ) and TNF inhibitors (TNFIs) in rheumatoid arthritis (RA) patients in clinical practice.
Via Krishan Maggon
Get Started for FREE
Sign up with Facebook Sign up with X
I don't have a Facebook or a X account
Your new post is loading...
Your new post is loading...
|
Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry
Ryoko Sakai†, Soo-Kyung Cho†, Toshihiro Nanki, Kaori Watanabe, Hayato Yamazaki, Michi Tanaka, Ryuji Koike, Yoshiya Tanaka, Kazuyoshi Saito, Shintaro Hirata, Koichi Amano, Hayato Nagasawa, Takayuki Sumida, Taichi Hayashi, Takahiko Sugihara, Hiroaki Dobashi, Shinsuke Yasuda, Tetsuji Sawada, Kazuhiko Ezawa, Atsuhisa Ueda, Takao Fujii, Kiyoshi Migita, Nobuyuki Miyasaka, Masayoshi Harigai* and for the REAL Study Group
*Corresponding author: Masayoshi Harigai mharigai.mpha@tmd.ac.jp
† Equal contributors
Author Affiliations
For all author emails, please log on.
Arthritis Research & Therapy 2015, 17:74 doi:10.1186/s13075-015-0583-8
Ryoko Sakai and Soo-Kyung Cho contributed equally to this work.
Published: 23 March 2015